Prometheus Biosciences, Inc.
RXDX
Rang în acțiuni
#3259
Prometheus Biosciences, Inc. is a biopharmaceutical company primarily focused... Prometheus Biosciences, Inc. is a biopharmaceutical company primarily focused on discovering, developing, and commercializing innovative therapeutics and complementary diagnostic products, mainly targeting inflammatory bowel diseases (IBD). Its flagship therapeutic candidate, PRA023, is a humanized IgG1 monoclonal antibody currently undergoing Phase IIa clinical trials. This investigational treatment is being evaluated for its potential in addressing ulcerative colitis and Crohn's disease, both forms of IBD, as well as systemic sclerosis-associated interstitial lung disease. Beyond its lead asset, Prometheus maintains an active development pipeline featuring several other programs targeting IBD and other immune-mediated conditions: PR600: An anti-tumor necrosis factor monoclonal antibody (mAb) for IBD. PR300: A small molecule G-protein coupled receptor modulator specifically for IBD. PR1100: An anti-cytokine receptor mAb with applications in IBD and various other immune disorders. PR1800: An anti-chemokine mAb focused on IBD. PR2100: An anti-inflammatory cytokine mAb also aimed at IBD. Furthermore, the company has forged key alliances, including a diagnostic development and collaboration pact with Takeda Pharmaceutical Company Limited, a co-development and manufacturing arrangement with Dr. Falk Pharma GmbH, a licensing agreement with Cedars-Sinai Medical Center, and a strategic partnership with Millennium Pharmaceuticals, Inc. Tracing its origins, the company was initially incorporated in 2016 as Precision IBD, Inc., before rebranding to Prometheus Biosciences, Inc. in October 2019. Its corporate headquarters are situated in San Diego, California.
Preț acțiune
$199.92
Ultima sincronizare: 2023-06-15
Capitalizare de piață
$5.39B
Schimbare (1 zi)
0.09%
Schimbare (1 an)
0.00%
Țară
US
Tranzacționează Prometheus Biosciences, Inc. (RXDX)
Categorie
Healthcare
Raport P/S pentru Prometheus Biosciences, Inc. (RXDX)
Raport P/S la data de October 2026 TTM: 1.40K
Conform celor mai recente rapoarte financiare și prețului acțiunilor Prometheus Biosciences, Inc., raportul P/S actual (TTM) este 1.40K. La sfârșitul anului 2021, compania avea un P/S de 395.96.
Istoricul raportului P/S pentru Prometheus Biosciences, Inc. din 2014 până în 2026
Raport P/S la sfârșitul fiecărui an
| An | Raport P/S | Schimbă |
|---|---|---|
| 2026 (TTM) | 1.40K | 113.94% |
| 2022 | 656.18 | 65.72% |
| 2021 | 395.96 | -44.40% |
| 2020 | 712.14 | 16.66% |
| 2019 | 610.42 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | -100.00% |
| 2014 | 3.09K | 0.00% |
Raport P/S pentru companii similare sau competitoare
| Companie | Raport P/S | Diferență raport P/S | Țara |
|---|---|---|---|
| 10.72 | -99.24% |
US
|
|
| 41.70 | -97.03% |
US
|
|
| 4.19 | -99.70% |
AU
|
|
| 5.80 | -99.59% |
BE
|
|
| 10.44 | -99.26% |
NL
|
